Dolutegravir with boosted darunavir treatment simplification for the transmitted HIV thymidine analog resistance in Manitoba, Canada

Int J STD AIDS. 2018 Apr;29(5):520-522. doi: 10.1177/0956462418760426.

Authors

J Wheeler¹, S Chan², P R Harrigan³, M Becker^{1

2

4

5}, K Kasper^{1

2}, Y Keynan^{1

2

4

5}

Affiliations

¹ 1 Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
² 2 Manitoba HIV Program, Winnipeg, Canada.
³ 3 BC Centre for Excellence in HIV/AIDS, Vancouver, Canada.
⁴ 4 Department of Medical Microbiology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
⁵ 5 Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.

PMID: 29513131
DOI: 10.1177/0956462418760426

No abstract available

Publication types

Letter

MeSH terms

Adult
Darunavir / administration & dosage*
Darunavir / economics
Darunavir / therapeutic use
Drug Administration Schedule
Drug Resistance, Viral / drug effects*
Female
HIV Infections / drug therapy*
HIV Integrase Inhibitors / administration & dosage*
HIV Integrase Inhibitors / economics
HIV Integrase Inhibitors / therapeutic use
HIV Protease Inhibitors / administration & dosage*
HIV Protease Inhibitors / economics
HIV Protease Inhibitors / therapeutic use
Heterocyclic Compounds, 3-Ring / administration & dosage*
Heterocyclic Compounds, 3-Ring / economics
Heterocyclic Compounds, 3-Ring / therapeutic use
Humans
Male
Oxazines
Piperazines
Pyridones
Retrospective Studies
Treatment Outcome
Viral Load / drug effects*

Substances

HIV Integrase Inhibitors
HIV Protease Inhibitors
Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
dolutegravir
Darunavir